SCHEMBL29323480

SCHEMBL29323480

Nc1cccc2c1ncn2[C@@H]1O[C@H](CO)[C@H](O)C1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.62
ADORA2A P29274 3/20 0.58
ADORA2B P29275 3/20 0.58
DPP4 P27487 1/20 0.58
MEN1 O00255 1/20 0.58
SLC28A1 O00337 1/20 0.58
MAP3K7 O43318 1/20 0.58
SLC28A2 O43868 1/20 0.58
GAPDH P04406 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
MAPK1 P28482 1/20 0.58
ADORA1 P30542 1/20 0.58
STAT6 P42226 1/20 0.58
PI4KA P42356 1/20 0.58
KMT2A Q03164 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PI4K2B Q8TCG2 1/20 0.58
DOT1L Q8TEK3 1/20 0.58
SLC29A1 Q99808 1/20 0.58
PI4K2A Q9BTU6 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29323111 1.00 KDM4E (0.62) KDM4EADORA2AADORA2BDPP4MEN1
SCHEMBL28573111 0.83 SMN1; SMN2 (0.58) KDM4EADORA2AADORA2BDPP4MEN1
SCHEMBL967479 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL1738519 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL31376058 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL12031134 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL17780621 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL20419184 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL11124342 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1
SCHEMBL29323163 0.82 SMN1; SMN2 (0.68) ADORA2AADORA2BDPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES EMORY UNIVERSITY 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES MTAP, PNP, SARS1 KDM4E 1179/4885ADORA2A 43/4885ADORA2B 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.